Yahoo Finance Zevra Therapeutics Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
Zevra Therapeutics (NASDAQ:ZVRA) Full Year 2023 Results
Key Financial Results
Revenue: US$27.5m (up 170% from FY 2022).
Net loss: US$46.0m (loss widened by 72% from FY 2022).
US$1.30 loss per share (further deteriorated from US$0.78 loss in FY 2022).
ZVRA Products In Clinical Trials
Phase I: 2.
Phase II: 1.
Phase III: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zevra Therapeutics Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 5.7%. Earnings per share (EPS) missed analyst estimates by 9.9%.
In the last 12 months, the only revenue segment was Pharmaceuticals contributing US$27.5m. The largest operating expense was Research & Development (R&D) costs, amounting to US$39.0m (53% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of US$3.56m. Explore how ZVRA's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 42% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Pharmaceuticals industry in the US.
Performance of the American Pharmaceuticals industry.
The company's shares are down 13% from a week ago.
Risk Analysis
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for Zevra Therapeutics that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
